TB-500 half-life & pharmacokinetics

Reported half-life

Estimated 1–3 hours (parenteral, rodent models); data sparse for fragment specifically

The half-life and pharmacokinetic profile of TB-500 reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• subcutaneous injection
• intraperitoneal injection
• topical application

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Synthetic thymosin beta-4 fragment; actin-binding peptide / tissue-regenerating agent

Mechanism context

Half-life interpretation depends on the underlying mechanism. TB-500 acts as follows:

TB-500 is the commercial designation for a synthetic peptide derived from residues 17 to 23 of thymosin beta-4 (Tβ4), encompassing the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln. This heptapeptide contains the principal G-actin-binding motif of the full 43-amino-acid parent protein — specifically the LKKTET sequence that interacts with subdomain 1 of monomeric actin. By binding and sequestering cytoplasmic G-actin, TB-500 influences the dynamic equilibrium between monomeric and filamentous actin (the G-F actin ratio), which in turn governs cytoskeletal organisation, cell polarity, and migratory capacity. This mechanism positions TB-500 as a promoter of directed cell migration — a prerequisite for wound closure, tendon-fibroblast infiltration, and vascular ingrowth.

See the full TB-500 research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.